ArticleGynecologic oncology reports2022

Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer.

Kaito Mimura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.